{"id":"W4401226031","doi":"10.1177/13524585241267211","title":"Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis","year":2024,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; St. Michael's Hospital; Cegep de Saint Jerome; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; F. Hoffmann-La Roche; Sanofi Genzyme; EMD Serono; Grifols; Monash University; Alexion Pharmaceuticals; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Atara Biotherapeutics; Medical Research Council; Biogen; Sanofi","keywords":"Medicine; Ocrelizumab; Cladribine; Multiple sclerosis; Natalizumab; Fingolimod; Alemtuzumab; Relapsing remitting; Expanded Disability Status Scale; Internal medicine; Gastroenterology; Oncology; Rituximab; Immunology; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002271768,0.0002494627,0.0006271641,0.0002418986,0.0001265969,0.0004649382,0.0002711564,0.0002861619,0.00101104],"category_scores_gemma":[0.003683222,0.0001013028,0.001002104,0.0001926025,0.0003131537,0.0002933681,0.0002408412,0.0004948798,0.00009457726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007901874,"about_ca_system_score_gemma":0.0003978255,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008779433,"about_ca_topic_score_gemma":0.001744353,"domain_scores_codex":[0.9989302,0.0006645376,0.00008535212,0.0001212406,0.0001221679,0.00007651461],"domain_scores_gemma":[0.9968437,0.001376919,0.001005119,0.0001947553,0.0001094303,0.0004700968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6869127,0.002119252,0.1370043,0.00113162,0.00699353,0.0001542246,0.0003103544,0.007478774,0.009255844,0.0003265723,0.001207178,0.1471057],"study_design_scores_gemma":[0.06445128,0.2353116,0.6561915,0.0006282198,0.009756601,0.001074602,0.0003036728,0.01479012,0.0119218,0.0007384407,0.004748965,0.00008319224],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957645,0.003410687,0.00007104377,0.0000998364,0.00002078016,0.00002376439,0.0001217514,0.000004012379,0.0004835546],"genre_scores_gemma":[0.9992291,0.0004417502,0.00007483821,0.00003468802,0.00001629666,0.000009812106,0.0001073919,0.000001099899,0.0000850882],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002271768,"threshold_uncertainty_score":0.01201445,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09020544279069158,"score_gpt":0.3128205917848402,"score_spread":0.2226151489941486,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}